This is likely due to its potential role in promoting resistance to chemotherapy and targeted therapy, as evidenced by the increased resistance to KRAS G12C inhibitors, such as sotorasib and adagrasib, which have shown limited efficacy in CRC compared to non-small cell lung cancer (NSCLC) [37,38]. Here, KRAS is linked to non-small cell lung carcinoma.